Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DT 200

Next Previous
Drug Profile

DT 200

Alternative Names: DT-200; G 100192; GLPG-0492; SARMs - Galapagos NV

Latest Information Update: 16 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ProSkelia
  • Developer Akashi Therapeutics; Galapagos NV
  • Class Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Duchenne muscular dystrophy
  • Discontinued Cachexia

Most Recent Events

  • 16 Oct 2025 Phase-I clinical trials in Duchenne muscular dystrophy (In volunteers) in United Kingdom (PO), prior to October 2025(EudraCT2016-004100-62)(Akashi Therapeutics pipeline, October 2025)
  • 22 Feb 2023 Preclinical development in Duchenne muscular dystrophy is ongoing in USA (PO) (Akashi therapeutics pipeline, February 2023)
  • 28 Oct 2018 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top